日本肺動脈性肺高血圧症治療薬市場規模、シェア、トレンドおよび薬剤クラス別、投与経路別、エンドユーザー別、リージョン別予測2025年~2033年

日本肺動脈性肺高血圧症治療薬市場規模、シェア、トレンドおよび薬剤クラス別、投与経路別、エンドユーザー別、リージョン別予測2025年~2033年

Report Format: PDF+Excel | Report ID: SR112025A36880

Language of the Report – English

ただし、追加料金で日本語のレポートが入手できる場合もある。

1    Preface
2    Scope and Methodology

2.1    Objectives of the Study
2.2    Stakeholders
2.3    Data Sources
2.3.1    Primary Sources
2.3.2    Secondary Sources
2.4    Market Estimation
2.4.1    Bottom-Up Approach
2.4.2    Top-Down Approach
2.5    Forecasting Methodology
3    Executive Summary
4    Japan Pulmonary Arterial Hypertension Drugs Market - Introduction

4.1    Overview
4.2    Market Dynamics
4.3    Industry Trends
4.4    Competitive Intelligence
5    Japan Pulmonary Arterial Hypertension Drugs Market Landscape
5.1    Historical and Current Market Trends (2019-2024)
5.2    Market Forecast (2025-2033)
6    Japan Pulmonary Arterial Hypertension Drugs Market - Breakup by Drug Class
6.1    Endothelin Receptor Antagonists (ERAs)
6.1.1    Overview
6.1.2    Historical and Current Market Trends (2019-2024)
6.1.3    Market Forecast (2025-2033)
6.2    Vasodilators
6.2.1    Overview
6.2.2    Historical and Current Market Trends (2019-2024)
6.2.3    Market Forecast (2025-2033)
6.3    Phosphodiesterase-5 (PDE-5) Inhibitors
6.3.1    Overview
6.3.2    Historical and Current Market Trends (2019-2024)
6.3.3    Market Forecast (2025-2033)
6.4    Soluble Guanylate Cyclase (SGC) Stimulators
6.4.1    Overview
6.4.2    Historical and Current Market Trends (2019-2024)
6.4.3    Market Forecast (2025-2033)
6.5    Calcium Channel Blockers (CCBs)
6.5.1    Overview
6.5.2    Historical and Current Market Trends (2019-2024)
6.5.3    Market Forecast (2025-2033)
6.6    Prostacyclin and Prostacyclin Analogs
6.6.1    Overview
6.6.2    Historical and Current Market Trends (2019-2024)
6.6.3    Market Forecast (2025-2033)
6.7    Others
6.7.1    Historical and Current Market Trends (2019-2024)
6.7.2    Market Forecast (2025-2033)
7    Japan Pulmonary Arterial Hypertension Drugs Market - Breakup by Route of Administration
7.1    Inhalation
7.1.1    Overview
7.1.2    Historical and Current Market Trends (2019-2024)
7.1.3    Market Forecast (2025-2033)
7.2    Injectable
7.2.1    Overview
7.2.2    Historical and Current Market Trends (2019-2024)
7.2.3    Market Forecast (2025-2033)
7.3    Oral Administration
7.3.1    Overview
7.3.2    Historical and Current Market Trends (2019-2024)
7.3.3    Market Forecast (2025-2033)
8    Japan Pulmonary Arterial Hypertension Drugs Market - Breakup by End User
8.1    Hospitals
8.1.1    Overview
8.1.2    Historical and Current Market Trends (2019-2024)
8.1.3    Market Forecast (2025-2033)
8.2    Clinics
8.2.1    Overview
8.2.2    Historical and Current Market Trends (2019-2024)
8.2.3    Market Forecast (2025-2033)
8.3    Others
8.3.1    Historical and Current Market Trends (2019-2024)
8.3.2    Market Forecast (2025-2033)
9    Japan Pulmonary Arterial Hypertension Drugs Market – Breakup by Region
9.1    Kanto Region
9.1.1    Overview
9.1.2    Historical and Current Market Trends (2019-2024)
9.1.3    Market Breakup by Drug Class
9.1.4    Market Breakup by Route of Administration
9.1.5    Market Breakup by End User
9.1.6    Key Players
9.1.7    Market Forecast (2025-2033)
9.2    Kansai/Kinki Region
9.2.1    Overview
9.2.2    Historical and Current Market Trends (2019-2024)
9.2.3    Market Breakup by Drug Class
9.2.4    Market Breakup by Route of Administration
9.2.5    Market Breakup by End User
9.2.6    Key Players
9.2.7    Market Forecast (2025-2033)
9.3    Central/ Chubu Region
9.3.1    Overview
9.3.2    Historical and Current Market Trends (2019-2024)
9.3.3    Market Breakup by Drug Class
9.3.4    Market Breakup by Route of Administration
9.3.5    Market Breakup by End User
9.3.6    Key Players
9.3.7    Market Forecast (2025-2033)
9.4    Kyushu-Okinawa Region
9.4.1    Overview
9.4.2    Historical and Current Market Trends (2019-2024)
9.4.3    Market Breakup by Drug Class
9.4.4    Market Breakup by Route of Administration
9.4.5    Market Breakup by End User
9.4.6    Key Players
9.4.7    Market Forecast (2025-2033)
9.5    Tohoku Region
9.5.1    Overview
9.5.2    Historical and Current Market Trends (2019-2024)
9.5.3    Market Breakup by Drug Class
9.5.4    Market Breakup by Route of Administration
9.5.5    Market Breakup by End User
9.5.6    Key Players
9.5.7    Market Forecast (2025-2033)
9.6    Chugoku Region
9.6.1    Overview
9.6.2    Historical and Current Market Trends (2019-2024)
9.6.3    Market Breakup by Drug Class
9.6.4    Market Breakup by Route of Administration
9.6.5    Market Breakup by End User
9.6.6    Key Players
9.6.7    Market Forecast (2025-2033)
9.7    Hokkaido Region
9.7.1    Overview
9.7.2    Historical and Current Market Trends (2019-2024)
9.7.3    Market Breakup by Drug Class
9.7.4    Market Breakup by Route of Administration
9.7.5    Market Breakup by End User
9.7.6    Key Players
9.7.7    Market Forecast (2025-2033)
9.8    Shikoku Region
9.8.1    Overview
9.8.2    Historical and Current Market Trends (2019-2024)
9.8.3    Market Breakup by Drug Class
9.8.4    Market Breakup by Route of Administration
9.8.5    Market Breakup by End User
9.8.6    Key Players
9.8.7    Market Forecast (2025-2033)
10    Japan Pulmonary Arterial Hypertension Drugs Market – Competitive Landscape
10.1    Overview
10.2    Market Structure
10.3    Market Player Positioning
10.4    Top Winning Strategies
10.5    Competitive Dashboard
10.6    Company Evaluation Quadrant
11    Profiles of Key Players
11.1    Company A 
11.1.1    Business Overview
11.1.2    Products Offered
11.1.3    Business Strategies
11.1.4    SWOT Analysis
11.1.5    Major News and Events
11.2    Company B
11.2.1    Business Overview
11.2.2    Products Offered
11.2.3    Business Strategies
11.2.4    SWOT Analysis
11.2.5    Major News and Events
11.3    Company C
11.3.1    Business Overview
11.3.2    Products Offered
11.3.3    Business Strategies
11.3.4    SWOT Analysis
11.3.5    Major News and Events
11.4    Company D 
11.4.1    Business Overview
11.4.2    Products Offered
11.4.3    Business Strategies
11.4.4    SWOT Analysis
11.4.5    Major News and Events
11.5    Company E
11.5.1    Business Overview
11.5.2    Products Offered
11.5.3    Business Strategies
11.5.4    SWOT Analysis
11.5.5    Major News and Events    

Company names have not been provided here as this is a sample TOC. The complete list is provided in the report.

12    Japan Pulmonary Arterial Hypertension Drugs Market - Industry Analysis
12.1    Drivers, Restraints, and Opportunities
12.1.1    Overview
12.1.2    Drivers
12.1.3    Restraints
12.1.4    Opportunities
12.2    Porters Five Forces Analysis
12.2.1    Overview
12.2.2    Bargaining Power of Buyers
12.2.3    Bargaining Power of Suppliers
12.2.4    Degree of Competition
12.2.5    Threat of New Entrants
12.2.6    Threat of Substitutes
12.3    Value Chain Analysis
13    Appendix

日本肺動脈性肺高血圧症治療薬市場規模、シェア、トレンドおよび薬剤クラス別、投与経路別、エンドユーザー別、リージョン別予測2025年~2033年
Purchase Options Discount
Offer
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials